|
 |
| home > ebr > winter 2003 > clinical applications of small molecule p38 map kinase inhibitors |
|
|
 PUBLICATIONS |
European BioPharmaceutical Review
|
| Tumour necrosis factor alpha (TNF-a) and interleukin-1 beta (IL-1b) are pro-inflammatory cytokines that play a key role in the communication between cellular components (leukocytes, macrophages, endothelial cells and so on) that drive inflammatory processes underlying a broad range of diseases. Injectable biological therapies specifically targeting the inhibition of TNF-a (infliximab and etanercept) or IL-1 (anakinra) are clinically validated in the treatment of rheumatoid arthritis (RA), psoriatic arthritis, psoriasis and Crohn's disease (CD). TNF inhibitors in particular have become a gold standard of disease-modifying treatment in patients with severe RA. |
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
EuroBiopartnering 2008
7-9 October 2008, Paris, France
EuroBiOpartnering
2008 gives you the unique opportunity to meet the relevant decision makers and
opinion leaders from the international biotech community and offers you 3 days
of partnering opportunities including one-to-one meetings, company presentations
and further networking activities…
More info >> |
|
 |
News and Press Releases |
 |
Azopharma Product Development Group, Inc
HOLLYWOOD, Fla. – Azopharma Product Development Group, Inc. (“Azopharma”) announced today the addition of innovative state-of-the-art equipment at its formulation and manufacturing division, ApiCross Drug Delivery Technologies in Hollywood, Florida. The most recent acquisition is the MG Futura Capsule Filler which delivers the latest in capsule filling technology. The company has also added a Bausch & Strobel Aseptic Filling Isolator, equipment that is ground-breaking in the powder filling process. These additions support our previously implemented XcelodoseTM powder micro-dosing system. With these technologies, Azopharma is able to provide its clients with all forms of the capsule filling process. The new equipment is part of Azopharma’s recent manufacturing expansion which includes 17 new manufacturing suites for GMP, cytotoxic and aseptic products...
More info >> |
|
 |
